INCY vs APTV Comparison

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Aptiv PLC is an industrial technology company focused on enabling a more automated, electrified and digitalized future. The company's technologies reach from sensor to cloud, including the hardware and software necessary to support automotive and other industries on a global basis. Its Advanced Safety and User Experience segment provides advanced software and services, intelligent sensors and high-performance compute platforms; its Engineered Components Group segment provides connection systems, high-performance interconnects, and cable management and protection solutions; and its Electrical Distribution Systems segment provides low voltage and high voltage power, signal and data distribution.